We are studying the safety and effectiveness of vemurafenib in children with BRAF mutation-resistant histiocytosis. This trial aims to find the best dosage and treatment duration for these young patients.
Health conditions and diseases that the clinical trial is designed to study and treat.
Histiocytic cell proliferation refers to a group of rare diseases characterized by the abnormal growth of histiocytes, which are immune cells that help fight infections. Conditions like Langerhans cell sarcoma and Erdheim-Chester disease fall under this category, leading to various symptoms depending on the affected areas of the body.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.